The science of ibogaine, from the forest to the clinic

Tabernanthe iboga

Tabernanthe iboga is a slow-growing subshrub native to the rainforests of Central and West Africa — Gabon, Cameroon, the Republic of Congo, and Equatorial Guinea. It reaches one to two metres in height, with small yellow-orange flowers, and is unremarkable in appearance. It is the root bark — gathered, dried, and powdered — that contains the plant's extraordinary pharmacology. The alkaloids are concentrated in the bark of the root, not the leaves or stem, and harvesting is traditionally done with precision: only what is needed, and with ceremony.

Gabon · Cameroon · Republic of Congo · Equatorial Guinea

A National Treasure

In 2000, the Council of Ministers of the Republic of Gabon formally declared Tabernanthe iboga a national treasure and cultural heritage strategic reserve — one of the few instances in which a sovereign government has explicitly protected a psychoactive plant for its cultural and spiritual significance. The declaration placed iboga under the same legal framework as Gabon's natural heritage, restricting export and anchoring the plant's future to its country of origin.^[13]

The Bwiti Tradition

The Bwiti religion of Central Africa is among the oldest continuous spiritual traditions on earth. It centres on the use of iboga — primarily the root bark — as a vehicle for healing, initiation, ancestor communication, and community repair. Two lineages are most significant: the Missoko (focused on healing and purification) and the Dissumba (focused on initiation and ancestral connection).

At the centre of every Bwiti ceremony is the Nganga — the healer and guide, trained over years or decades in the preparation and administration of iboga, the containment of the ceremonial space, and the interpretation of what arises. The Nganga does not observe from outside; they accompany the initiate through the experience.

Two modes of use exist within the tradition: the flood dose (sometimes called the full initiation dose) — a large, extended experience that can last 24 to 36 hours and is used for initiation and major transformation — and maintenance doses, smaller and more frequent, used for ongoing healing, spiritual practice, and community ritual.

The Bwiti initiation is understood as a rebirthing. The initiate symbolically dies — crossing from one state of being to another — and returns with new understanding, new identity, and a renewed relationship with their community and ancestors.

In the Bwiti cosmological frame, the visionary journey that iboga produces is not hallucination. It is a literal visit to the realm of the ancestors — an opportunity to receive wisdom, resolve inherited wounds, and return carrying that knowledge into life. This framing has been practised and refined over millennia. Modern neuroscience is only now beginning to understand why it works.

Voices of the Tradition

The Scholarly Record

James W. Fernandez

Professor Emeritus of Anthropology, University of Chicago

Author of the foundational English-language academic text on Bwiti — winner of the 1983 Herskovits Prize.

+

Fernandez began fieldwork in Gabon in 1960, working among the Fang people on the Bwiti religion. His landmark book — Bwiti: An Ethnography of the Religious Imagination in Africa — remains the foundational English-language academic text on the tradition. It won the 1983 Herskovits Prize from the African Studies Association.

WebsiteLinkedIn

Fernandez JW. Bwiti: An Ethnography of the Religious Imagination in Africa. Princeton University Press, 1982. [11]

Giorgio Samorini

Independent ethnobotanist

Author of the most comprehensive scholarly series on iboga ritual history currently available.

+

Samorini's ongoing series Studies on the Iboga Cults, published in the peer-reviewed journal Antrocom: Journal of Anthropology (2024–2025), is the most comprehensive scholarly analysis of the history and ritual practice of iboga use currently available. The papers are freely accessible at antrocom.net.

Website

Samorini G. Studies on the iboga cults. Antrocom: Journal of Anthropology. 2024–2025. [12]

A Family of Compounds, Not a Single Molecule

Tabernanthe iboga root bark contains at least 12 identified alkaloids in the iboga structural family. This is not a simple plant with one active compound — it is a pharmacological ecosystem. Many practitioners and researchers believe the full alkaloid profile of the root bark produces effects that pure synthetic ibogaine alone cannot fully replicate, though this remains an active area of investigation.

The lead alkaloids are ibogaine, noribogaine, tabernanthine, ibogamine, and coronaridine — with ibogaine and its metabolite noribogaine being the most clinically studied.

Ibogaine — The Lead Compound

Ibogaine is the primary psychoactive alkaloid in Tabernanthe iboga root bark. It is responsible for the acute visionary experience and the majority of the receptor-binding activity that scientists have characterised. Once ingested, ibogaine is metabolised primarily by the CYP2D6 enzyme in the liver — converting it to noribogaine. People who are CYP2D6 poor metabolisers (a genetic variation affecting roughly 7–10% of the population) convert ibogaine more slowly, accumulating more of it in the bloodstream. This is why genetic screening before treatment is a standard part of responsible medical ibogaine protocols.

Ibogaine half-life: approximately 4–7 hours

Obach RS, Pablo J, Mash DC. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos. 1998;26(8):764–768.^[2]

Noribogaine — Where the Real Work Happens

Ibogaine is not, by itself, the whole story. When the liver processes ibogaine, the primary product is noribogaine — and noribogaine is not a passive metabolic byproduct. It is a pharmacologically active compound in its own right, and it behaves in ways that are fundamentally different from its parent molecule.

Noribogaine half-life: 28–49 hours — compared to ibogaine's 4–7 hours

After ibogaine has cleared the body, noribogaine persists in the bloodstream for days. The sustained anti-craving window that patients consistently report — dramatically reduced cravings for days or even weeks after a single treatment — appears to correlate directly with noribogaine plasma levels, not ibogaine.

Noribogaine is a G-protein-biased kappa-opioid receptor agonist: it binds kappa opioid receptors in a way that reduces craving without triggering the sedation and dysphoria that classic kappa agonists produce. This biased binding mechanism is one of the most significant pharmacological findings in ibogaine science.^[3]

The following table summarises the major alkaloids identified in Tabernanthe iboga root bark, their approximate prevalence, and their primary known pharmacological action.

01

Ibogaine

Most abundant · 1–3% of root bark dry weight

The primary psychoactive — a 36–72 hour journey through neurological reset.

Serotonin transporter (SERT) reuptake inhibitorNMDA receptor non-competitive antagonistSigma-1 and sigma-2 receptor agonistKappa-opioid receptor weak agonisthERG potassium channel blocker (cardiac relevance)

Ibogaine is the compound responsible for the acute visionary experience and the dramatic interruption of addiction signalling. Its broad multi-receptor activity is both its therapeutic signature and the source of its complexity — it acts simultaneously on systems that regulate craving, mood, memory consolidation, and consciousness.

The hERG channel blockade prolongs the QTc interval and is the primary safety concern requiring cardiac screening before treatment.

MW

310.43 g/mol

Half-life

4–7 hours (converted to noribogaine)

02

Noribogaine

12-hydroxyibogamine

Major active metabolite · formed in the liver via CYP2D6

The silent workhorse — responsible for weeks of sustained anti-craving benefit.

Biased kappa-opioid receptor agonist (G-protein selective)Mu-opioid receptor partial agonistSerotonin transporter (SERT) ligandLess hERG activity than ibogaine

While ibogaine provides the acute experience, noribogaine carries the therapeutic weight. Its 28–49 hour half-life means patients remain in an altered neurochemical state long after the visionary phase ends. Dr. Debra Mash’s research identified noribogaine as the compound responsible for the sustained reduction in cravings and withdrawal symptoms — a finding that opened the door to noribogaine as a potential standalone pharmaceutical.

DemeRx (acquired by ATAI Life Sciences) completed a Phase 1 trial of ibogaine HCl in 2022, with noribogaine as a central focus for next-generation drug development.

Half-life

28–49 hours

03

Tabernanthine

Second most abundant alkaloid in root bark

The structural sibling that shapes iboga's analgesic and sedative character.

Partial opioid receptor agonistSome cardiovascular activity (adrenergic effects)Mild CNS depressant properties

Tabernanthine shares the ibogamine backbone but carries distinct pharmacological properties. As the second most abundant alkaloid, it likely contributes to the sedative and analgesic dimensions of the iboga experience — the profound physical relaxation that practitioners describe as necessary for the inner journey. The interplay between tabernanthine and ibogaine within the full-spectrum root bark preparation may contribute to the "entourage" character of traditional ceremonial use compared to isolated ibogaine.

Half-life

Not well characterised

04

Ibogamine

Minor alkaloid

The structural archetype from which the iboga alkaloid family descends.

CNS and cardiovascular activity (less studied)Structurally the simplest iboga-type alkaloidSome serotonin system interaction proposed

Ibogamine is the base scaffold of the iboga alkaloid family — ibogaine and noribogaine are its derivatives. Though present in smaller concentrations and pharmacologically less characterised than the major alkaloids, its structural role in biosynthesis makes it scientifically significant. Research into ibogamine has informed understanding of the structure-activity relationships that govern the whole alkaloid family, contributing to the development of synthetic ibogaine analogues.

05

Coronaridine

18-Methoxycoronaridine (18-MC)

Minor alkaloid · synthetic derivative under active clinical development

The drug-development lead — anti-addictive potency without the full psychedelic profile.

Alpha-3 beta-4 nicotinic acetylcholine receptor antagonistSignificantly less hERG activity than ibogaine (lower cardiac risk)Dopamine system modulation via VTA

Coronaridine and its synthetic analogue 18-MC (developed by Dr. Stanley Glick at Albany Medical College) represent the strongest pathway from iboga's pharmacology to regulated pharmaceutical medicine. By targeting alpha-3 beta-4 nicotinic receptors — which sit upstream of dopamine release in the reward circuit — 18-MC interrupts the craving signal without producing the 36–72 hour visionary state or the cardiac risk profile of ibogaine. This selectivity makes it the most clinically tractable iboga-derived compound for mainstream addiction medicine.

Salix Pharmaceuticals licensed 18-MC from Albany Medical College and has pursued IND approval for addiction indications.

06

Voacangine

Present in root bark · abundant in Voacanga africana bark

The biosynthetic gateway — the plant's precursor to ibogaine itself.

Direct precursor in ibogaine biosynthesis (enzymatic O-methylation)Some receptor activity of its own (opioid, adrenergic)Lower psychoactivity than ibogaine

Voacangine occupies a unique position: it is both a pharmacologically active alkaloid and the plant kingdom's raw material for producing ibogaine. Voacanga africana — a related West African tree — contains voacangine in high concentrations and has become the primary source for semi-synthetic ibogaine production at scale. As global demand for ibogaine grows and conservation concerns around Tabernanthe iboga intensify, voacangine extraction and chemical conversion is emerging as the most sustainable supply pathway.

Semi-synthetic ibogaine from voacangine is increasingly the preferred supply source for clinical trials and licensed treatment.

07

Iboluteine

Trace amounts

The frontier alkaloid — present, but its role remains an open question.

Pharmacological profile not well characterisedStructural relative of ibogaineArea of ongoing ethnopharmacological study

Iboluteine is present in the root bark in trace quantities and has received limited scientific attention compared to the major alkaloids. Its structural relationship to ibogaine suggests potential CNS activity, but the absence of rigorous pharmacological data means its contribution to the overall iboga effect profile is unknown. It represents the wider pattern of iboga research: a handful of well-studied compounds surrounded by a larger class of alkaloids whose roles in both the plant's ecology and human pharmacology remain largely unmapped.

08

Other alkaloids identified in T. iboga

Beyond the seven primary compounds, Tabernanthe iboga root bark contains a broader class of indole alkaloids whose pharmacological profiles are only partially characterised. Their presence may contribute to the whole-plant preparation's distinct character relative to isolated ibogaine.

IbogalineKirunineGabonineCatharonineIbogalidineKisantineDimethoxyibogaline3-HydroxycoronaridineVoacristinePseudoibogaineHeyneanineDesethylibogamine

Receptor Sites — Tap to Explore

Each site below represents a different way ibogaine interacts with the brain. Tap a receptor to see what it does in plain English.

DopamineSerotoninGABAACh / NicotinicSigma-1VTASigma-2

Click a system box on the diagram above, or tap a label below, to explore ibogaine's mechanism at that receptor site.

A Note on Cardiac Safety

Ibogaine also blocks hERG potassium channels in the heart — an effect that delays the heart's electrical repolarisation and can cause QT prolongation. This is why cardiac screening (ECG, electrolyte panel, medical history) and continuous ECG monitoring throughout treatment are non-negotiable requirements of any responsible ibogaine protocol. At Nekawa, ibogaine is administered inside a fully licensed hospital with ICU-level cardiac monitoring.^[8]

Thurner P et al. Block of hERG channels by the indole alkaloid ibogaine. J Pharmacol Exp Ther. 2014;348(3):346–357.

The VTA — Resetting the Reward Circuit

The ventral tegmental area (VTA) is the origin of the brain's mesolimbic dopamine system — the reward pathway that addiction hijacks. VTA dopamine neurons project to the nucleus accumbens (the brain's primary reward centre) and to the prefrontal cortex.

In an addicted brain, this system becomes dysregulated. The 'allostatic set point' shifts: the brain requires drugs simply to feel normal, while natural rewards — food, connection, purpose — feel flat and motivationless. This is not a moral failure. It is a neurological state.

Ibogaine appears to temporarily suppress and then allow the resetting of VTA dopamine neuron firing patterns — not simply blocking or flooding the system, but enabling a recalibration toward the pre-addiction baseline. The mechanism is complex and still being characterised, but the clinical observation — dramatically reduced cravings in the days following treatment — is consistent across thousands of patients.

Dalibor Sames, Ph.D.

Columbia University · Scientific co-founder, Gilgamesh Pharmaceuticals

Mapping ibogaine's molecular architecture to design safer analogues that preserve therapeutic efficacy while reducing cardiac and duration risk.

+

Dr. Dalibor Sames leads the Sames Lab at Columbia University's Department of Chemistry and is a scientific co-founder of Gilgamesh Pharmaceuticals, a company developing ibogaine-inspired medicines designed to preserve therapeutic efficacy while reducing cardiac and duration risk. His lab's structure-activity relationship research has mapped which aspects of ibogaine's molecular architecture drive its effects on mesolimbic dopamine circuitry — foundational work for the next generation of ibogaine-derived therapies.

WebsiteLinkedIn

Glick SD et al. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem Biol. 2001;56:39–53. [6]

The Window of Wonder

One of ibogaine's most significant and least understood properties is what it does after the acute experience ends: it reopens a state of heightened brain plasticity that the brain normally only experiences during early childhood.

Neuroscientists call these 'critical periods' — windows of time when the brain is maximally malleable, when learning and rewiring happen at a pace impossible in the adult brain. Once these windows close during development, they were long thought to be closed permanently. Ibogaine appears to reopen them.

Dr. Gül Dölen

UC Berkeley · Helen Wills Neuroscience Institute

Discovered ibogaine keeps the brain's social reward learning window open longer than any other known psychedelic — by a wide margin.

+

Dölen's lab published a landmark study in Nature (2023) showing that psychedelics reopen the social reward learning critical period in mice. The comparison across compounds was striking — and ibogaine produced the longest reopening by a wide margin.

Website

Nardou R, Sawyer E, Song YJ, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618(7966):790–798. DOI: 10.1038/s41586-023-06204-3. PMID: 37316665. [1]

"Ibogaine, which produces this crazy long trip that in humans lasts three days, keeps the critical period in mice open for more than a month — and we haven't tested the closure."

"If you engineer these drugs to have a shorter, acute subjective effect, which is what a lot of companies are trying to do, you're going to get rid of the therapeutic efficacy of these drugs."

What Happens During a Session

The typical progression: onset within 1–3 hours of ingestion; peak visionary experience from hours 4 to 8; a reflective, integrative phase from hours 8 to 20; residual sensitivity and afterglow for the following 24–48 hours. Throughout, the patient rests in a monitored room — ataxia (loss of coordination), sensitivity to sound and light, and the intensity of the inner experience make physical activity inadvisable and unnecessary. This is not something to be rushed.

The Bwiti Frame: Rebirthing, Rite of Passage, Ancestor Work

In the Bwiti tradition, the flood dose initiation is not understood as therapeutic in the Western clinical sense — it is a rite of passage. A crossing. The initiate is understood to symbolically die — to move from one state of being to another — and to return with new understanding, new identity, and a renewed relationship with community and ancestors. The Bwiti word for this transformation does not translate neatly into English. It describes a quality of having-been-somewhere-and-returned-changed.

In the Bwiti cosmological frame, the visionary experience is understood as a literal visit to the realm of the ancestors — those who have gone before and whose wisdom is available to the living if accessed through the right means. Iboga is that means. The Nganga's role is to guide the initiate through this territory safely, to interpret what arises, and to help integrate it into ongoing life.

What makes this framework remarkable — from a modern neuroscience perspective — is that it may be describing, in experiential terms, exactly what the neuroscience is showing in physiological terms. The brain during ibogaine is in a state of heightened plasticity, the Window of Wonder. The oneiric content of that state — the autobiographical review, the encounter with patterns, the sense of receiving understanding from somewhere outside ordinary thought — is the psychological material the open window allows to be processed and rewired. The Bwiti tradition has, over millennia, developed a ceremonial container precisely designed to make the most of that state.

Modern Interpretation

Contemporary therapy frameworks use the ibogaine experience as an extended period of introspective review. Patients frequently report watching their life's patterns — the roots of addiction, trauma, or depression — from a detached, observational perspective, as if reviewing a film of their own history. The emotional charge that ordinarily makes these memories unbearable is temporarily suspended, and the brain is sufficiently plastic to process and reframe them. This is not a cure. It is an opening — and what fills that opening, in the weeks of integration that follow, determines the depth of healing.

Nekawa's 28-day program is designed precisely to fill this window. The days before treatment prepare the nervous system; the days and weeks after — in nature, in community, with somatic support — are where the brain's extraordinary plasticity is given something worth wiring.

The Open Questions

• →What determines the length of the Window of Wonder in individual humans — and can it be extended through integration practices?
• →Do whole-plant preparations of Tabernanthe iboga produce different effects than synthetic ibogaine, and if so, which alkaloids are responsible?
• →What are the long-term neuroplasticity effects across different populations, conditions, and treatment protocols?
• →Can the cardiac risk of ibogaine be reliably separated from the therapeutic mechanism — and what do drugs like Tabernanthalog (TBG) or other ibogaine analogues teach us?
• →What can the Bwiti tradition — with its millennia of empirical knowledge about preparation, ceremony, and integration — teach modern medicine about how to conduct these experiences responsibly?

You Are Part of This Story

Ibogaine research is one of the most active frontiers in neuroscience and psychiatry today. Veterans programmes. Stanford trials. MAPS protocols. The VA. Researchers at Johns Hopkins, Columbia, UC Berkeley, and dozens of other institutions are working to understand what the Bwiti people of Gabon have always known. The people seeking healing right now — at clinics like Nekawa — are participants in that frontier. Their outcomes, their recoveries, their willingness to step into something that mainstream medicine is only beginning to understand, is part of what builds the evidence base that will change treatment globally.

Landri Ekomie-Obame — Popo, as he is known in Bwiti — and Charles Johnston, Nekawa co-founder, after Charles's iboga initiation.

An Invitation

This is a story that is not finished. It is being written now, by scientists and by patients, by Nganga and by neuroscientists, by people who have tried everything else and found that ibogaine gave them something no other approach could: a window. What you do with the window is yours. We would like to help you open it.